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LETTERS TO THE EDITOR
The use of erythropoietin in a Jehovah's Witness undergoing major
surgery and chemotherapy
Sir -The use of recombinant erythropoietin to correct the
anaemia ofchronic renal failure is well described (Winearls et
al., 1986; Eschbach et al., 1987), as is its use in situations
where endogenous erythropoietin production is normal or
elevated, such as rheumatoid arthritis (Means et al., 1987),
and in facilitating autologous blood transfusion (Goodnough
et al., 1988). We report the case of a man whose religious
beliefs prevented him from accepting transfusions who was
able to recover from major surgery and undergo intensive
myelotoxic chemotherapy using erythropoietin to maintain
near-normal haemoglobin level. The use of erythropoietin in
this situation has not been reported previously.
The patient was a 36 year-old male Jehovah's Witness who
presented with a 5 month history of lumbar back pain. A
computed tomographic scan of the abdomen showed a large
retroperitoneal mass invading the right psoas and surround-
ing the inferior vena cava. An initial needle biopsy suggested
a soft tissue sarcoma and he therefore underwent laparotomy
with a de-bulking procedure. The tumour was highly vascular
and the operation resulted in considerable blood loss with a
fall in the haemoglobin from 12.6gdl-l to 3.66gdl-'. No
transfusion was given, in accordance with the patient and his
family's firmly-stated wishes. Human Recombinant Erythro-
poietin was started on the 4th post-operative day at a dose of
4,000 units three times per week, together with daily iron and
folic acid supplements. The haemoglobin rose at a rate of
1 g dl-' every 4 days during his recovery from the operation,
which was complicated by the development of a deep venous
thrombosis.
Histology of the mass showed not sarcoma, but a primary
extragonadal yolk-sac tumour and he therefore went on to
receive combination chemotherapy with a regime consisting
of Bleomycin (15 mg), Etoposide (120 mgm2) and Cis-
platinum (40mgm2) each day for the first 3 days of a 21
day cycle. This was repeated four times. Each cycle of treat-
ment was accompanied by severe neutropenia (WHO Grade
4) but the haemoglobin was well maintained throughout,
above 9.5 g dl-1. Shortly after the first chemotherapy was
given the prothrombin time fell briefly and signs of further
propagation of his venous thrombosis developed with swell-
ing of the lower half of the body. A duplex scan confirmed
occlusion of the vena cava by thrombus and treatment was
instituted with a continuous infusion of streptokinase at
100,000 units per hour for 4 days, after which time the signs
had resolved. Thereafter a further heparin infusion was given
for 14 days followed by re-warfarinisation.
The chemotherapy was successful, the tumour markers
falling within the normal range by the end of the third cycle,
with no evidence of a residual mass on follow-up computed
tomographic scans. Erythropoietin was discontinued at the
end of the fourth cycle of treatment. Serum iron levels were
low throughout (2-10smoll-1) with reduced iron binding
capacity (44 tmoll1'). Ferritin levels were normal through-
out.
This case illustrates the potential usefulness of erythro-
poietin in raising haemoglobin in those patients unable for
ideological or other reasons to receive transfusions. Whilst
the rapid recovery in haemoglobin during the post-operative
period is probably not significantly faster than expected in a
well nourished previously fit man (a rise of 2 g dl week is the
norm during treatment of iron-deficiency anaemia), the main-
tenance of this level throughout a 3 month period of myelo-
toxic chemotherapy is unusual: The average transfusion
requirement of patients receiving this regime is 1 to 2 units
per cycle, even without the added effects of thrombolytic
treatment and anticoagulation to which this patient was sub-
ject. It may be that erythropoietin exerts some protective
effect against drug-induced erythroid precursor depletion.
In view of previous reports of thrombotic problems in
patients with chronic renal failure receiving erythropoietin
(Winearls et al., 1986; Casati et al., 1987; Eschbach et al.,
1987) it seems possible that a similar effect may have
precipitated or exacerbated the episodes of caval thrombosis
which this patient experienced.
The treatment ofJehovah's Witnesses with intensive chemo-
therapy is always difficult. The necessity to avoid transfusion
often leads to curtailment or reduction of drug doses and
eradication of potentially curable tumours such as teratoma
and high-grade lymphoma may be made impossible as a
result. If the use of erythropoietin eliminates the need for
transfusion this would provide a valuable complement in the
management of such patients.
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